This is the moment for change

To truly change medicine, you need the tools to develop treatments that provide the greatest benefit to patients who need them. We have those here, at Ichnos Sciences—with our in-house platform that will accelerate our efforts in drug discovery. Our pioneering technology platform supports the work we do every day in oncology, enabling us to create new biologics that have the potential to become the therapies that could change lives—and the world.

Technology shifted
device

Technology shifted


Significant advancements have been made in the treatment of cancer, especially as new immuno-oncology therapies are investigated.1 But there is still work to do to accelerate the pace at which highly effective therapies are available to patients.

We see this challenge as an opportunity.


device

Significant advancements have been made in the treatment of cancer, especially as new immuno-oncology therapies are investigated.1 But there is still work to do to accelerate the pace at which highly effective therapies are available to patients.

We see this challenge as an opportunity.


The BEAT® platform offers an entirely new way to treat cancers—both today and well into the future.6

Inspired by nature and building on past scientific advancements, we developed our novel, patented BEAT® (Bispecific Engagement by Antibodies based on the T cell receptor) platform. Combined with our disease-centric approach, the BEAT platform has the potential to deliver real progress in some of the most challenging therapeutic areas.

How BEAT® is writing a new chapter in medicine

A next-generation approach to immuno-oncology, BEAT is designed to enable more efficient production of bispecific antibodies that can engage multiple targets simultaneously, enhancing the power of the immune system to fight disease.6

The BEAT bispecific antibodies have two separate arms built into one antibody. One arm binds to a T cell—a central element of immune response—while the other binds to specific targets on different types of tumor cells.6 The BEAT platform uses this process to activate and localize cancer-fighting immune cells where they’re needed to attack disease, killing neighboring tumor cells that otherwise may not have been recognized as a threat.7

Offering advanced optimization of manufacturing and scale, the BEAT platform is built with patented  T cell Receptor (TCR) Technology, replacing the traditional antibody backbone with TCR components.6,8 This approach improves the stability and high-yield purification of multispecific antibodies with limitless targeting potential, which may allow BEAT candidates to be developed to fight a wide range of diseases.6,8

1.

Burugu, S., Dancsok, A. R. & Nielsen, T. O. Emerging targets in cancer immunotherapy. Seminars in Cancer Biology 52, 39–52 (2018).

6.

Skegro, D. et al. Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies. J. Biol. Chem. 292, 9745–9759 (2017).

7.

Wu, Z. & Cheung, N. V. T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics. Pharmacology and Therapeutics 182, 161–175 (2018).

8.

Fagète, S. et al. Dual display: phage selection driven by co-engagement of two targets by two different antibody fragments. 30, 575–582 (2017).

View Career Opportunities

United States

Switzerland

India

You are now leaving the Ichnos Sciences Inc. website.


The link you have selected is provided for your convenience, and Ichnos is not responsible for content, privacy or security issues associated with your visit to external websites.


Cancel Continue

You are now leaving the Ichnos Sciences Inc. website.


The link you have selected is provided for your convenience, and Ichnos is not responsible for content, privacy or security issues associated with your visit to external websites.


Cancel Continue